OBJECTIVE: To systematically review the efficacy and safety of dipeptidyl peptidase-4 (DPP-4) inhibitors versus glucagon like peptide-1 (GLP-1) receptor agonists for type 2 diabetes mellitus (T2DM). METHODS: Databases including EMbase, PubMed, The Cochrane Library, Clinical Trial, CBM, CNKI and WanFang Data, were searched electronically for randomized controlled trials (RCTs) of DPP-4 inhibitors versus GLP-1 receptor agonists for T2DM up to December 2015. Two reviewers independently screened literatures according to the inclusion and exclusion criteria, extracted data, and assessed the methodological quality of the included studies. Then Meta-analysis was performed using RevMan 5.3 soft ware. RESULTS: A total of 13 RCTs were included. The results of Meta-analysis showed that compared with DPP-4- inhibitors, GLP-1 receptor agonists were more effective in reducing the levels of fasting plasma glucose [MD = 0.93, 95% CI (0.48, 1.38), P < 0.0001] and glycated hemoglobin [ MD = 0.53, 95% CI (0.34, 0.73), P<0.00001] andBMI [MD = 1.53, 95% CI(0.83, 2.22), P <0.001]. However, DPP-4 inhibitors were more effective than GLP-1 receptor agonists in the reducing the 2-hour postprandial blood glucose level. And GLP-1 receptor agonists were more prone to cause gastrointestinal adverse reactions than DPP-4 inhibitors [RR =0.44,95% CI (0.33, 0.59), P <0.0001]. CONCLUSION GLP-1 receptor agonists are superior to DPP-4 inhibitors in controlling the fasting plasma glucose and glycated hemoglobin levels and reducing the body weight of T2DM patients, while DPP-4 inhibitors have better efficacy in reducing 2-hour postprandial blood glucose level, with better tolerability.

Focused on nanobiology and nanomedicine, this article elucidates its main research targets and contents, discusses the important of researches in this field, introduces the tasks and objectives of the corresponding researches in the national long- and mid-term science and technology development planning, and also describes the present research status in China.
Biology ; trends ; China ; Nanomedicine ; trends ; Nanotechnology ; trends

Drug Therapy, Combination ; Follow-Up Studies ; Hepatitis B e Antigens ; blood ; Hepatitis B, Chronic ; drug therapy ; Humans ; Lamivudine ; administration & dosage ; Thymus Hormones ; administration & dosage ; Vidarabine Phosphate ; administration & dosage

Antiviral Agents ; therapeutic use ; Female ; Hepatitis B virus ; Hepatitis B, Chronic ; drug therapy ; Humans ; Pregnancy ; Pregnancy Complications ; drug therapy ; virology

OBJECTIVETo observe the renal injury in rats induced by Longdan Xiegan decoction (LDXGD) containing different dosages Aristolochia manshriensis.

METHODSD rats were divided into four groups at random, and were fed with three kinds of LDXGD 13, 14.5, 17.5 g x kg(-1) (containing respectively A. manshriensis 1.5, 3, 6 g x kg(-1)) and distilled water respectively for 12 weeks. Renal functional parameters on 4,8,12 w were determined and changes of histomorphology in rats on the end of experiment were observed.

RESULTThe LDXGD containing low dose (1.5 g x kg(-1)) A. manshriensis did't induce significantly renal injury in rats during 12 weeks; the LDXGD containing midst dose(3 g x kg(-1)) A. manshriensis induced light damage of proximal convoluted tubule epithelial cells in rats during 12 weeks; the LDXGD containing high dose(6 g x kg(-1)) A. manshriensis induced significantly renal injury in rats after administed 4 weeks. Along with the lasting of administration, the degree of injury became more seriously. The main renal injury location was in proximal convoluted tubule.

CONCLUSIONThe renal toxicity of LDXGD is correlated with the dose of A. manshriensis and the time of administration. The LDXGD containing low dose A. manshriensis has relative security. However, the LDXGD containing high dose A. manshriensis can induce renal injury.

Acetylglucosaminidase ; urine ; Animals ; Aristolochia ; chemistry ; toxicity ; Blood Urea Nitrogen ; Creatinine ; blood ; Dose-Response Relationship, Drug ; Drug Combinations ; Drugs, Chinese Herbal ; administration & dosage ; isolation & purification ; toxicity ; Kidney Diseases ; chemically induced ; metabolism ; pathology ; Kidney Tubules, Proximal ; drug effects ; pathology ; Male ; Plants, Medicinal ; chemistry ; toxicity ; Proteinuria ; chemically induced ; Random Allocation ; Rats ; Rats, Sprague-Dawley ; beta 2-Microglobulin ; urine ; gamma-Glutamyltransferase ; urine

3',4'-Di-O-(S)-comphanoyl-(+)-cis-khellactone (DCK) is a synthetic khellactone ester that exhibits potent anti-HIV activity with a mechanism distinct from clinically used anti-HIV agents. Several series of DCK analoges have been synthesized and evaluated for inhibitory effects against HIV. This review article describes recent progress in the discovery, structural modification, and structure-activity relationship studies of potent anti-HIV DCK derivatives.
Anti-HIV Agents ; chemical synthesis ; chemistry ; pharmacology ; Biological Availability ; Camphor ; analogs & derivatives ; chemical synthesis ; chemistry ; pharmacology ; Coumarins ; chemical synthesis ; chemistry ; pharmacology ; HIV ; drug effects ; HIV Reverse Transcriptase ; antagonists & inhibitors ; Humans ; Lactones ; chemical synthesis ; chemistry ; pharmacology ; Structure-Activity Relationship

OBJECTIVETo observe the renal function, histology and the levels of interleukin-1beta (IL-1beta), interleukin-6 (IL-6) in rats administered with Aristolochi manshriensis (AM) and Longdan Xiegan decoction (LDXG) containing AM.

METHODDivided SD rats into control, AM and LDXG groups (n = 10 per group) at random and administrated orally for 8 weeks with distilled water, AM (6 g x kg(-1) x d(-1)) and LDXG (17. 5 g x kg(-1) x d(-1), containing AM 6 g x kg(-1) x d(-1)), respectively. Measured renal functional parameters in serum, urine and IL-1beta, IL-6 in renal homogenate, and observe renal histologic lesions at the end of 8 weeks.

RESULTTwo kinds of water abstract induced significantly renal injury in rats, IL-1beta, IL-6 levels in renal homogenate were significantly increased compared with controls, histological section showed inflammatory cell infiltration play important role in renal tubulointerstitium damage. LDXG caused less seriously damage than AM.

CONCLUSIONAM and LDXG in experimental dosage can induce renal injury, inflammatory cell infiltration in renal tubulointerstitium and high levels of IL-1beta, IL-6 presumpt that the nephrotoxicity of AM and LDXG refered to the immune mechanism. LDXG has light nephrotoxicity due to its restraining the inflammatory reaction caused by AM.

Administration, Oral ; Animals ; Aristolochia ; chemistry ; Blood Urea Nitrogen ; Creatinine ; blood ; Drug Combinations ; Drugs, Chinese Herbal ; administration & dosage ; isolation & purification ; toxicity ; Interleukin-1beta ; metabolism ; Interleukin-6 ; metabolism ; Kidney ; drug effects ; metabolism ; pathology ; Kidney Tubules ; drug effects ; metabolism ; pathology ; Male ; Plants, Medicinal ; chemistry ; Proteinuria ; blood ; chemically induced ; Random Allocation ; Rats ; Rats, Sprague-Dawley

OBJECTIVETo study whether the abilities of hepatitis C virus (HCV) E2 gene immunization to induce humoral and cellular immune responses to E2 protein were affected by hepatitis B virus (HBV) preS gene when they fused in DNA-immunized mice.

METHODSMice were immunized with E2, preS-E2 (preS gene was upstream of E2 gene), and E2-preS (preS gene was downstream of E2 gene) gene by their eukaryotic expression vectors, respectively. The anti-E2 or anti-preS antibodies were detected using the E2 and preS antigens. The cellular immune response to E2 protein in immunized mice was presented by its survival time after injecting SP2/O myeloma cells expressing HCV E2 protein into the abdominal cavity.

RESULTSChimeric E2 and preS gene immunization can induce mice to develop anti-preS and anti-E2 antibodies. The number of the mice developing anti-E2 antibody and the antibody titers in preS-E2 gene-injected group were higher than those in E2-preS gene-immunized group. However, the mice injected with E2 gene did not develop the detectable anti-E2 antibodies until 12 weeks after DNA immunization. After the mice was injected with target cells, the average survival time of the mice in the group immunized with E2 gene alone was longer than that of the group injected with E2 gene fused with HBV preS and was significantly longer than that of the control (P < 0.05).

CONCLUSIONHBV preS might be a humoral enhancer that can affect the abilities of HCV E2 protein to induce immune responses in DNA-immunized mice.

Animals ; Antibody Formation ; drug effects ; Hepacivirus ; chemistry ; Hepatitis B Surface Antigens ; genetics ; pharmacology ; Hepatitis B virus ; chemistry ; genetics ; Immunity, Cellular ; drug effects ; Male ; Mice ; Mice, Inbred BALB C ; Protein Precursors ; genetics ; pharmacology ; Recombinant Fusion Proteins ; immunology ; Viral Envelope Proteins ; genetics ; pharmacology

OBJECTIVETo investigate the predictive value of HCV RNA in PBMC of patients with chronic hepatitis C to IFN treatment.

METHODSThe HCV RNAs in PBMC were detected at the end of treatment, and 24 week and 1 year follow up after end treatment, in 16 patients who acquired complete response to IFN in 12 weeks of 24 weeks therapy.

RESULTS9 patients were HCV RNA positive in their PBMC at the end of treatment, the serum HCV RNA of 8 turned positive after 24 weeks and 1 year follow-up. In 7 patients with negative HCV RNA in PBMC, only two patients relapsed in serum HCV RNA after 1 year follow-up, and others remained viral response after 3.5 years.

CONCLUSIONHCV RNA in PBMC at the end of treatment was a predictor of the durable response to antiviral therapy in chronic hepatitis C.

Adult ; Female ; Hepatitis C, Chronic ; drug therapy ; virology ; Humans ; Interferon-alpha ; therapeutic use ; Leukocytes, Mononuclear ; virology ; Male ; Middle Aged ; RNA, Viral ; blood ; Recombinant Proteins

Antiviral Agents ; therapeutic use ; Hepatitis C, Chronic ; drug therapy ; Humans ; Ribavirin ; therapeutic use